GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...

This content was published on Oct 26, 2024 The Swiss Federal Democratic Union (EDU) has handed in referendum signatures to seek a vote to prevent the Eurovision Song Contest (ESC) from taking ...

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

全球医疗保健公司GSK plc (LSE/NYSE: GSK)今天宣布了正在进行的临床试验的初步数据,这些数据表明其呼吸道合胞病毒(RSV)疫苗Arexvy可能对更广泛的成年人群有效。 目前,Arexvy已在50多个国家获准用于60岁及以上人群,在美国和欧洲获准用于50-59岁高风险人群。新数据可能将RSV保护范围扩大到18-49岁有基础疾病的成年人和免疫功能低下的成年人。 III期临床试验(NC ...

GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...